Current and Novel Approach for Influenza vaccines

The first and foremost efforts to develop influenza vaccines were initiated soon after influenza A and B viruses were identified as the etiologic agents of clinical influenza. The United States in 1945 has approved the first commercial vaccines using whole-inactivated influenza virus for use. The flu vaccine is an annual vaccination using a vaccine to protect against the highly variable influenza virus that is specific for a given year. Risk management and effectiveness of vaccines are important for public health.

  • Genetic and evolution of virus and host
  • Risk management and effectiveness of vaccines
  • Targeting strategies for influenza vaccines
  • Clinical trials of influenza based vaccines

Related Conference of Current and Novel Approach for Influenza vaccines

October 30-November 1, 2017

3rd Annual Congress on Rare Diseases and Orphan Drugs


(10 Plenary Forums - 1 Event)
San Antonio, Texas, USA
November 06-07, 2017

3rd International Conference on Flu and Emerging Infectious Diseases

Las Vegas, Nevada, USA
March 1-2, 2018

5th International congress on Infectious Diseases

Berlin, Germany
June 11-12, 2018

4th World Congress on Rare Diseases and Orphan Drugs

Dublin, Ireland
July 23-25, 2018

11th World Congress on Infectious Diseases and Therapy

Melbourne, Australia
August 27-28, 2018

9th International Conference on Emerging Infectious Diseases

Zurich, Switzerland
September 17-18, 2018

4th Annual Congress on Infectious Diseases

San Diego, USA
September 27-29, 2018

10thEuro-Global Conference on Infectious Diseases

Rome, Italy

Current and Novel Approach for Influenza vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in